04/06/2026
BULLETIN: A Multi-Incident Analysis of Reports Associated with Newer Insulins
Newer insulin products consist of biosimilars and faster-acting, longer-acting, or higher-concentration analogues.
This safety bulletin describes a multi-incident analysis of reports involving newer insulin products and shares recommendations to enhance their safe use.
Health care providers are encouraged to review their current processes and implement suggested improvements to support and promote the safe prescribing, transcribing, dispensing, and administration of insulin products.
Learn more: https://ismpcanada.ca/bulletin/insulins-mia/